Lucinda Quan
Plus aucun poste en cours
Fortune : 134 682 $ au 30/06/2024
Profil
Lucinda Y.
Quan is the founder.
She founded Aligos Therapeutics, Inc. in 2018 and served as the Chief Business Officer, EVP & General Counsel until 2023.
She also held former positions at Merck & Co., Inc. from 2016 to 2018 as the Executive Director-Business Development, at InterMune, Inc. from 2004 to 2013 as the VP-Legal Affairs & Associate General Counsel, and at Alios BioPharma, Inc. from 2013 to 2016 as the Vice President & Head-Legal Affairs.
Ms. Quan received her undergraduate and graduate degrees from the University of California, Los Angeles.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/09/2023 | 384 805 ( 0,51% ) | 134 682 $ | 30/06/2024 |
Anciens postes connus de Lucinda Quan
| Sociétés | Poste | Fin |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Fondateur | 01/12/2023 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/04/2018 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Conseiller Juridique Général | 01/01/2016 |
| INTERMUNE INC | Conseiller Juridique Général | 01/11/2013 |
Formation de Lucinda Quan
| University of California, Los Angeles | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
